在心力衰竭住院患者中,左心室射出分数和ICD-10代码之间的关系
Ty J Gluckman1, Shih-Ting Chiu1, Deanna Rider2
1Center for Cardiovascular Analytics, Research, and Data Science (CARDS), Providence Heart Institute, Providence Health System, Portland, Oregon, USA.
Clinical cardiology
|December 17, 2024
概括
左心室喷射分数 (LVEF) 的分布因心力衰竭 (HF) 类型而异. 虽然系统性HF患者通常具有较低的LVEF,但扩张性HF患者通常保留了LVEF,突出了分类细微差别.
科学领域:
- 心脏病学 心脏病学
- 心脏衰竭研究研究
- 临床信息学 临床信息学
背景情况:
- 左心室喷射分数 (LVEF) 对于对心力衰竭 (HF) 的分类至关重要.
- 基于ICD-10代码的不同高频分类的LVEF分布存在有限的数据.
- 了解这种分布对于准确的患者分层和管理至关重要.
研究的目的:
- 分析住院心力衰竭患者中LVEF的分布.
- 为了将LVEF与特定的国际疾病分类 (ICD) - - 10对心力衰竭类型的代码相关联.
- 评估ICD-10定义的高频类型和测量的LVEF之间的一致性.
主要方法:
- 从2018年1月到2022年10月,对61,238例高风住院病人的回顾性横截面分析.
- 包括使用特定ICD-10代码 (静心,透心,组合,高血压心脏病) 主要HF诊断的患者.
- 在住院治疗前3个月内分析了49772名患者的心声回声扫描的LVEF数据.
主要成果:
- 观察到 LVEF 和 ICD-10 代码之间的高度一致性,用于静缩性高血压 (LVEF ≤ 40%) 和静缩性高血压 (LVEF ≥ 50%).
- 综合性HF:86.2%的LVEF≤40%;透析性HF:94.0%的LVEF≥50%.
- 与HF和CKD相关的高血压心脏病显示LVEF值的范围更广.
结论:
- ICD-10代码与LVEF对不同类型的HF (心缩,心径,组合) 具有很好的一致性.
- 然而,这些特定的HF代码仅占HF住院总数的一小部分 (~10%).
- 需要进一步的研究来了解更广泛的高频人口中的LVEF分布.
相关概念视频
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Imbalances in Cardiac Output
1.3K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K
01:26Heart Failure Drugs: Inotropic Agents
516
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
516
01:22Heart Failure Drugs: β-Blockers
315
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
315
01:22Heart Failure Drugs: Diuretics
339
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
339
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
382
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
382